Abstract:Abstract Human epidermal growth factor receptor 2 (HER2)-positive breast cancer and triple negative breast cancer (TNBC) are two subtypes with poor outcome of all breast carcinomas. However, among all the patients in these two subtypes some still yielded relatively better prognosis. Ribonucleotide reductase (RR) small subunits M2 was associated with cancer cell invasiveness and metastasis, which prognoses poor survival in many cancers. Here we investigated whether RRM2 could serve as a prognostic biomarker for breast cancers, especially HER2- positive and TNBC subgroups. One hundred seventy five assessable breast cancers (40 cases were HER2-positive or TNBC) were collected from affiliated hospital of Zhejiang University (ZJU set); and six published microarray data sets (total 1154 cases, 63 cases were identified as HER2- positive or TNBC) with pathoclinical and follow- up information were employed for validation. In the ZJU set, the protein level of RRM2 was determined by IHC. It was indicated that RRM2 was positively correlated with cell proliferative marker Ki-67 (trends P=0.018) and stem/progenitor cell marker CD44+/CD24-/low (P=0.044). Multivariate COX model revealed that RRM2 was an independent prognostic biomarker for both OS (Hazard Ratio, HR=2.79, 95%Cl 1.21-6.75) and PFS (Hazard Ratio, HR=1.82, 95%Cl 1.02-3.26) for all the breast cancers. Moreover, in HER2-positive or TNBC breast cancers, RRM2-high was significantly associated with poor survival (P=0.025). Consequently, none of the patients with RRM2-low died of breast cancer in HER2-positive or TNBC subgroups. Furthermore, above findings were validated in the published data sets. The mRNA level of RRM2 evaluated significantly in highly-invasive subtypes including Luminal B, HER2-positive and TNBC in comparison with Luminal A and unclassified subgroups (P<0.05). Overexpression of RRM2 was positively associated with poor differentiation (P<0.05), advanced AJCC stage (P<0.05) as well as poor survival (P<0.05) in a dose-dependent manner. It was also revealed that high expression of RRM2 prognosed poor survival (HR=5.56, 95% CI 1.14-99.9) in HER2-positive breast cancers or TNBC. Moreover, the RRM2-high (protein or mRNA levels) was associated with better response to chemotherapy comparing to RRM2-low. Taken together, the above findings suggested that RRM2 was a potential biomarker for poor survival in breast cancer, especially in HER2- positive breast cancer and TNBC. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 706. doi:1538-7445.AM2012-706

Comprehensive bioinformatics analysis of ribonucleoside diphosphate reductase subunit M2(RRM2) gene correlates with prognosis and tumor immunotherapy in pan-cancer

Prognostic and Immunological Potential of Ribonucleotide Reductase Subunits in Liver Cancer

RRM1, TUBB3, TOP2A, CYP19A1, CYP2D6: Difference Between Mrna and Protein Expression in Predicting Prognosis of Breast Cancer Patients

Comprehensive Landscape of RRM2 with Immune Infiltration in Pan-Cancer

Ribonucleotide Reductase Large Subunit M1 Predicts Poor Survival Due To Modulation Of Proliferative And Invasive Ability Of Gastric Cancer

A Pan-Cancer Analysis of the Oncogenic Role of Ribonucleotide Reductase Subunit M2 in Human Tumors

A comprehensive analysis of ribonucleotide reductase subunit M2 for carcinogenesis in pan-cancer

Ribonucleotide Reductase Small Subunit M2 Serves As a Prognostic Biomarker and Predicts Poor Survival of Colorectal Cancers

Over-expression of RRM2 predicts adverse prognosis correlated with immune infiltrates: A potential biomarker for hepatocellular carcinoma

Abstract 706: Ribonucleotide Reductase Small Subunit M2 is a Potential Prognostic Biomarker in Human Epidermal Growth Factor Receptor 2- Positive and Triple Negative Breast Cancers

The Potential of Ribonucleotide Reductase M2 As a Novel Prognostic Maker and Therapeutic Target to Inhibit Medulloblastoma Proliferation, Migration, and Invasiveness

Prognostic and therapeutic significance of ribonucleotide reductase small subunit M2 in estrogen-negative breast cancers

RecQ mediated genome instability 2 (<i>RMI2</i>): a potential prognostic and immunological biomarker for pan-cancers

High expression of RRM2 mediated by non-coding RNAs correlates with poor prognosis and tumor immune infiltration of hepatocellular carcinoma

Prognostic significance of protein expressions of ribonueleotide reductase subunits RRM1, RRM2 and RRM2B in hepatocellular carcinoma

High RRM2 expression has poor prognosis in specific types of breast cancer

Ribonucleotide Reductase M2 (RRM2): Regulation, Function and Targeting Strategy in Human Cancer.

RRM1 Gene Expression in Peripheral Blood is Predictive of Shorter Survival in Chinese Patients with Advanced Non-Small-cell Lung Cancer Treated by Gemcitabine and Platinum

Ribonucleotide Reductase M2 Subunit Expression and Prognostic Value in Nasopharyngeal Carcinoma

Overexpression of RRM2 is Related to Poor Prognosis in Oral Squamous Cell Carcinoma.

Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer